Serum Calprotectin Is a Potential Marker in Patients with Asthma
Yun-Gi Lee, Jisu Hong, Pureun‐Haneul Lee, June-Hyuk Lee, Sung Woo Park, Do-Jin Kim, An‐Soo Jang
Abstract
BACKGROUND: Calprotectin is the major cytosolic protein in neutrophil granulocytes. Although asthma is known to cause eosinophilic inflammation, some patients with asthma have non-eosinophilic inflammation, which is characterized by local neutrophilic inflammation. The aim of this study was to assess calprotectin expression levels in a mouse model of asthma, and to observe the relationship of serum calprotectin level and clinical variables in patients with asthma. METHODS: , respectively; mice treated with saline were used as a control. The levels of calprotectin were determined using enzyme-linked immunosorbent assay, immunoblotting, and immunohistochemical analysis. The serum levels of calprotectin were also assessed in patients with asthma. The relationship between calprotectin and clinicopathological characteristics was determined. RESULTS: = 0.004) in patients with asthma. CONCLUSION: Our data suggest that calprotectin could potentially be used as a biomarker for asthma.